TxCell: Regen Med Firm's CEO Starts From Scratch
Executive Summary
Since becoming CEO of TxCell two years ago, Stéphane Boissel has reorganized the R&D plan, restructured and reduced the head count and put the company on the road to scalable manufacturing of CAR-T regulatory cells. And he has put strategic partnerships on the agenda. It is a big change from the situation 12 months ago, he told In Vivo during the Annual European Advanced Therapies Investor Day.
You may also be interested in...
Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases
Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.
Billions On The Line With Celgene’s Partnered Pipeline
Celgene’s fourth quarter and 2016 sales aligned with previously disclosed double-digit gains as the company outlined later-stage pipeline programs expected to add billions in sales during the next five years.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.